GSK: new oncology data at ESMO and FDA accelerated approval of Jemperli in rectal cancer
FROM THE WIRE · FINANCE.YAHOO.COM
GSK (LSE:GSK) presented new late stage oncology data at the ESMO Congress on Jemperli, Mo-Rez and Ris-Rez in October 2026. Jemperli received FDA accelerated approval for MSI-H/dMMR locally advanced rectal cancer, enabling some patients to avoid chemotherapy, radiation and…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishOncology progress at a large pharma group can support its commercial outlook.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Jemperli received FDA accelerated approval for MSI-H/dMMR locally advanced rectal cancer.
- 02Mo-Rez and Ris-Rez showed encouraging efficacy signals in difficult tumor settings.
- 03The data were presented at the ESMO Congress in October 2026.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets